All In Biotech

Drug Trial Radar · NCT03822559

A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension

A Randomized, Double-masked, Controlled Parallel Group, Multi-center Study of DE-111A (Fixed Dose Combination of Tafluprost and Timolol Eye Drops) on the Treatment of Open Angle Glaucoma or Ocular Hypertension (With Tafluprost Eye Drops as a Comparator)

Last checked: Nov 20, 2026Latest source record: Jul 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 219 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

219

Actual

Start

Jan 20, 2019

Primary completion

Apr 4, 2023

Study completion Apr 4, 2023

Sponsor

Sponsor type
Industry
First posted
Jan 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a time, once daily for 3 months) is superior to the monotherapy of tafluprost 0.0015% eye drops administered one drop a time, once daily for 3 months) in subjects with open-angle glaucoma or ocular hypertension in China as well as comparison of safety.

Conditions

  • Open-angle Glaucoma, Ocular Hypertension

Interventions

  • A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mLDrug

    One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.

  • A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLDrug

    One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the average diurnal IOP (intraocular pressure)Time frame: Three months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Aier Eye Hospital Group Co., Ltd Changsha Aier Eye Hospital

    Changsha, China

  • Eye & Ent Hospital of Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.